Malignant progenitors from patients with acute myelogenous leukemia are sensitive to a diphtheria toxin-granulocyte-macrophage colony-stimulating factor fusion protein

Donna E. Hogge, Cheryl L. Willman, Robert J. Kreitman, Marc Berger, Philip D. Hall, Kenneth J. Kopecky, Chris McLain, Edward P. Tagge, Connie J. Eaves, Arthur E. Frankel

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

We have previously demonstrated that human granulocyte-macrophage colony-stimulating factor (GM-CSF) fused to a truncated diphtheria toxin (DT388-GMCSF) kills acute myelogenous leukemia (AML) cell lines bearing the GM-CSF receptor. We now report that exposure of malignant cells from 50 different patients with AML for 48 hours in culture to DT388-GMCSF reduces by a median of 1.6 logs (range, 0 to 3.7 logs) the number of leukemic cells capable of forming colonies in semisolid media (leukemic colony-forming cells [CFU-L]) with a median IC50 of 3 x 10-12 mol/L (range, 5 to >4,000 x 10-12 mol/L). Furthermore, the cell kill is dependent on the presence of high-affinity GM-CSF receptors on leukemic blasts, because CFU-L from 27 of 28 AML samples expressing ≤35 GM-CSF receptors per cell were inhibited by the toxin, whereas the colony growth from all 4 leukemic samples (2 AML, 1 acute lymphoblastic leukemia [ALL], and 1 prolymphocytic leukemia [PLL]) that had less than 35 receptors per cell was unaffected by the drug. Sensitivity of CFU-L to DT388-GMCSF was seen regardless of the clinical responsiveness of the patient's leukemia to standard chemotherapy agents. In contrast, clonogenic cells from normal bone marrow formed colonies at near control numbers after exposure to much higher toxin concentrations (4 x 10-9 mol/L) than those required to kill CFU-L from most patients. Thus, leukemic progenitors isolated directly from the peripheral blood of most AML patients show the same sensitivity to DT388-GMCSF as previously demonstrated for AML cell lines. Under the same conditions of exposure, normal hematopoietic progenitors are relatively unaffected by DT388-GMCSF, suggesting its potential as a therapeutic agent in AML.

Original languageEnglish (US)
Pages (from-to)589-595
Number of pages7
JournalBlood
Volume92
Issue number2
StatePublished - Jul 15 1998

Fingerprint

Granulocyte-Macrophage Colony-Stimulating Factor Receptors
Diphtheria Toxin
Granulocyte-Macrophage Colony-Stimulating Factor
Acute Myeloid Leukemia
Fusion reactions
Bearings (structural)
Cells
Proteins
Chemotherapy
Bone
Blood
Prolymphocytic Leukemia
Cell Line
Pharmaceutical Preparations
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Bone Marrow Cells
Inhibitory Concentration 50
Leukemia
Cell Count
Drug Therapy

ASJC Scopus subject areas

  • Hematology

Cite this

Malignant progenitors from patients with acute myelogenous leukemia are sensitive to a diphtheria toxin-granulocyte-macrophage colony-stimulating factor fusion protein. / Hogge, Donna E.; Willman, Cheryl L.; Kreitman, Robert J.; Berger, Marc; Hall, Philip D.; Kopecky, Kenneth J.; McLain, Chris; Tagge, Edward P.; Eaves, Connie J.; Frankel, Arthur E.

In: Blood, Vol. 92, No. 2, 15.07.1998, p. 589-595.

Research output: Contribution to journalArticle

Hogge, DE, Willman, CL, Kreitman, RJ, Berger, M, Hall, PD, Kopecky, KJ, McLain, C, Tagge, EP, Eaves, CJ & Frankel, AE 1998, 'Malignant progenitors from patients with acute myelogenous leukemia are sensitive to a diphtheria toxin-granulocyte-macrophage colony-stimulating factor fusion protein', Blood, vol. 92, no. 2, pp. 589-595.
Hogge, Donna E. ; Willman, Cheryl L. ; Kreitman, Robert J. ; Berger, Marc ; Hall, Philip D. ; Kopecky, Kenneth J. ; McLain, Chris ; Tagge, Edward P. ; Eaves, Connie J. ; Frankel, Arthur E. / Malignant progenitors from patients with acute myelogenous leukemia are sensitive to a diphtheria toxin-granulocyte-macrophage colony-stimulating factor fusion protein. In: Blood. 1998 ; Vol. 92, No. 2. pp. 589-595.
@article{a153a5c487c24b5a8debaccc70b84205,
title = "Malignant progenitors from patients with acute myelogenous leukemia are sensitive to a diphtheria toxin-granulocyte-macrophage colony-stimulating factor fusion protein",
abstract = "We have previously demonstrated that human granulocyte-macrophage colony-stimulating factor (GM-CSF) fused to a truncated diphtheria toxin (DT388-GMCSF) kills acute myelogenous leukemia (AML) cell lines bearing the GM-CSF receptor. We now report that exposure of malignant cells from 50 different patients with AML for 48 hours in culture to DT388-GMCSF reduces by a median of 1.6 logs (range, 0 to 3.7 logs) the number of leukemic cells capable of forming colonies in semisolid media (leukemic colony-forming cells [CFU-L]) with a median IC50 of 3 x 10-12 mol/L (range, 5 to >4,000 x 10-12 mol/L). Furthermore, the cell kill is dependent on the presence of high-affinity GM-CSF receptors on leukemic blasts, because CFU-L from 27 of 28 AML samples expressing ≤35 GM-CSF receptors per cell were inhibited by the toxin, whereas the colony growth from all 4 leukemic samples (2 AML, 1 acute lymphoblastic leukemia [ALL], and 1 prolymphocytic leukemia [PLL]) that had less than 35 receptors per cell was unaffected by the drug. Sensitivity of CFU-L to DT388-GMCSF was seen regardless of the clinical responsiveness of the patient's leukemia to standard chemotherapy agents. In contrast, clonogenic cells from normal bone marrow formed colonies at near control numbers after exposure to much higher toxin concentrations (4 x 10-9 mol/L) than those required to kill CFU-L from most patients. Thus, leukemic progenitors isolated directly from the peripheral blood of most AML patients show the same sensitivity to DT388-GMCSF as previously demonstrated for AML cell lines. Under the same conditions of exposure, normal hematopoietic progenitors are relatively unaffected by DT388-GMCSF, suggesting its potential as a therapeutic agent in AML.",
author = "Hogge, {Donna E.} and Willman, {Cheryl L.} and Kreitman, {Robert J.} and Marc Berger and Hall, {Philip D.} and Kopecky, {Kenneth J.} and Chris McLain and Tagge, {Edward P.} and Eaves, {Connie J.} and Frankel, {Arthur E.}",
year = "1998",
month = "7",
day = "15",
language = "English (US)",
volume = "92",
pages = "589--595",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "2",

}

TY - JOUR

T1 - Malignant progenitors from patients with acute myelogenous leukemia are sensitive to a diphtheria toxin-granulocyte-macrophage colony-stimulating factor fusion protein

AU - Hogge, Donna E.

AU - Willman, Cheryl L.

AU - Kreitman, Robert J.

AU - Berger, Marc

AU - Hall, Philip D.

AU - Kopecky, Kenneth J.

AU - McLain, Chris

AU - Tagge, Edward P.

AU - Eaves, Connie J.

AU - Frankel, Arthur E.

PY - 1998/7/15

Y1 - 1998/7/15

N2 - We have previously demonstrated that human granulocyte-macrophage colony-stimulating factor (GM-CSF) fused to a truncated diphtheria toxin (DT388-GMCSF) kills acute myelogenous leukemia (AML) cell lines bearing the GM-CSF receptor. We now report that exposure of malignant cells from 50 different patients with AML for 48 hours in culture to DT388-GMCSF reduces by a median of 1.6 logs (range, 0 to 3.7 logs) the number of leukemic cells capable of forming colonies in semisolid media (leukemic colony-forming cells [CFU-L]) with a median IC50 of 3 x 10-12 mol/L (range, 5 to >4,000 x 10-12 mol/L). Furthermore, the cell kill is dependent on the presence of high-affinity GM-CSF receptors on leukemic blasts, because CFU-L from 27 of 28 AML samples expressing ≤35 GM-CSF receptors per cell were inhibited by the toxin, whereas the colony growth from all 4 leukemic samples (2 AML, 1 acute lymphoblastic leukemia [ALL], and 1 prolymphocytic leukemia [PLL]) that had less than 35 receptors per cell was unaffected by the drug. Sensitivity of CFU-L to DT388-GMCSF was seen regardless of the clinical responsiveness of the patient's leukemia to standard chemotherapy agents. In contrast, clonogenic cells from normal bone marrow formed colonies at near control numbers after exposure to much higher toxin concentrations (4 x 10-9 mol/L) than those required to kill CFU-L from most patients. Thus, leukemic progenitors isolated directly from the peripheral blood of most AML patients show the same sensitivity to DT388-GMCSF as previously demonstrated for AML cell lines. Under the same conditions of exposure, normal hematopoietic progenitors are relatively unaffected by DT388-GMCSF, suggesting its potential as a therapeutic agent in AML.

AB - We have previously demonstrated that human granulocyte-macrophage colony-stimulating factor (GM-CSF) fused to a truncated diphtheria toxin (DT388-GMCSF) kills acute myelogenous leukemia (AML) cell lines bearing the GM-CSF receptor. We now report that exposure of malignant cells from 50 different patients with AML for 48 hours in culture to DT388-GMCSF reduces by a median of 1.6 logs (range, 0 to 3.7 logs) the number of leukemic cells capable of forming colonies in semisolid media (leukemic colony-forming cells [CFU-L]) with a median IC50 of 3 x 10-12 mol/L (range, 5 to >4,000 x 10-12 mol/L). Furthermore, the cell kill is dependent on the presence of high-affinity GM-CSF receptors on leukemic blasts, because CFU-L from 27 of 28 AML samples expressing ≤35 GM-CSF receptors per cell were inhibited by the toxin, whereas the colony growth from all 4 leukemic samples (2 AML, 1 acute lymphoblastic leukemia [ALL], and 1 prolymphocytic leukemia [PLL]) that had less than 35 receptors per cell was unaffected by the drug. Sensitivity of CFU-L to DT388-GMCSF was seen regardless of the clinical responsiveness of the patient's leukemia to standard chemotherapy agents. In contrast, clonogenic cells from normal bone marrow formed colonies at near control numbers after exposure to much higher toxin concentrations (4 x 10-9 mol/L) than those required to kill CFU-L from most patients. Thus, leukemic progenitors isolated directly from the peripheral blood of most AML patients show the same sensitivity to DT388-GMCSF as previously demonstrated for AML cell lines. Under the same conditions of exposure, normal hematopoietic progenitors are relatively unaffected by DT388-GMCSF, suggesting its potential as a therapeutic agent in AML.

UR - http://www.scopus.com/inward/record.url?scp=20244379085&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20244379085&partnerID=8YFLogxK

M3 - Article

C2 - 9657759

AN - SCOPUS:20244379085

VL - 92

SP - 589

EP - 595

JO - Blood

JF - Blood

SN - 0006-4971

IS - 2

ER -